Natera Inc. has announced initial translational research results from the international randomized Phase III PALLAS study, evaluating the use of Signatera™ molecular residual disease (MRD) testing in patients with high and intermediate risk HR+/HER2- breast cancer. The data, presented at the San Antonio Breast Cancer Symposium (SABCS), were generated from a U.S. biomarker cohort of 420 patients. Results indicate that MRD status, measured by the Signatera Genome test after surgery and adjuvant therapy, is a highly prognostic biomarker for distant recurrence risk in stage II-III HR+/HER2- breast cancer. Additional data from a parallel ex-US cohort and a treatment subgroup analysis will be presented at a later date.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251210806608) on December 11, 2025, and is solely responsible for the information contained therein.